» Articles » PMID: 35876574

ATP Bioluminescence Assay To Evaluate Antibiotic Combinations Against Extensively Drug-Resistant (XDR) Pseudomonas Aeruginosa

Abstract

Time-kill curves are used to study antibiotic combinations, but the colony count method to obtain the results is time-consuming. The aim of the study was to validate an ATP assay as an alternative to the conventional colony count method in studies of antibiotic combinations. The cutoff point for synergy and bactericidal effect to categorize the results using this alternative method were determined in Pseudomonas aeruginosa. The ATP assay was performed using the GloMax 96 microplate luminometer (Promega), which measures bioluminescence in relative light units (RLU). To standardize this assay, background, linearity, and the detection limit were determined with one strain each of multidrug-resistant P. aeruginosa and Klebsiella pneumoniae. Twenty-four-hour time-kill curves were performed in parallel by both methods with 12 strains of P. aeruginosa. The conventional method was used as a "gold" standard to establish the pharmacodynamic cutoff points in the ATP method. Normal saline solution was established as washing/dilution medium. RLU signal correlated with CFU when the assay was performed within the linear range. The categorization of the pharmacodynamic parameters using the ATP assay was equivalent to that of the colony count method. The bactericidal effect and synergy cutoff points were 1.348 (93% sensitivity, 81% specificity) and 1.065 (95% sensitivity, 89% specificity) log RLU/mL, respectively. The ATP assay was useful to determine the effectiveness of antibiotic combinations in time-kill curves. This method, less laborious and faster than the colony count method, could be implemented in the clinical laboratory workflow. Combining antibiotics is one of the few strategies available to overcome infections caused by multidrug-resistant bacteria. Time-kill curves are usually performed to evaluate antibiotic combinations, but obtaining results is too laborious to be routinely performed in a clinical laboratory. Our results support the utility of an ATP measurement assay using bioluminescence to determine the effectiveness of antibiotic combinations in time-kill curves. This method may be implemented in the clinical laboratory workflow as it is less laborious and faster than the conventional colony count method. Shortening the obtention of results to 24 h would also allow an earlier guided combined antibiotic treatment.

Citing Articles

Bioluminescent Pseudomonas aeruginosa and Escherichia coli for whole-cell screening of antibacterial and adjuvant compounds.

Farkas E, McKay G, Hu L, Nekouei M, Ho P, Moreira W Sci Rep. 2024; 14(1):31039.

PMID: 39730767 PMC: 11681086. DOI: 10.1038/s41598-024-81926-6.


A novel rapid bioluminescence-based antimicrobial susceptibility testing method based on adenosine triphosphate consumption.

Sever E, Aybakan E, Besli Y, Karatuna O, Kocagoz T Front Microbiol. 2024; 15:1357680.

PMID: 38404596 PMC: 10885693. DOI: 10.3389/fmicb.2024.1357680.


Analytical and bioluminescence-based non-invasive quality assessment of differentially grown strawberry ( Duch. 'Asia') during household refrigeration storage.

Jocsak I, Vegvari G, Klasz K, Andrassy-Baka G, Somfalvi-Toth K, Varga-Visi E Heliyon. 2023; 9(7):e18358.

PMID: 37539170 PMC: 10395523. DOI: 10.1016/j.heliyon.2023.e18358.


Comparison of coliform paper test and ATP bioluminescence assay for monitoring the disinfection of kitchen utensils in canteens of hebei, China.

Tang Y, Sun J, Dong D, Zhang X, Jia R, Wang Y Heliyon. 2023; 9(4):e14839.

PMID: 37025863 PMC: 10070920. DOI: 10.1016/j.heliyon.2023.e14839.

References
1.
Aragones L, Escude C, Visa P, Salvi L, Moce-Llivina L . New insights for rapid evaluation of bactericidal activity: a semi-automated bioluminescent ATP assay. J Appl Microbiol. 2012; 113(1):114-25. DOI: 10.1111/j.1365-2672.2012.05320.x. View

2.
Marchand S, Lamarche I, Gobin P, Couet W . Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. J Antimicrob Chemother. 2010; 65(8):1753-8. DOI: 10.1093/jac/dkq183. View

3.
Mathers A, Peirano G, Pitout J . The role of epidemic resistance plasmids and international high-risk clones in the spread of multidrug-resistant Enterobacteriaceae. Clin Microbiol Rev. 2015; 28(3):565-91. PMC: 4405625. DOI: 10.1128/CMR.00116-14. View

4.
Smith P, Ballow C, Booker B, Forrest A, Schentag J . Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients. Clin Ther. 2001; 23(8):1231-44. DOI: 10.1016/s0149-2918(01)80103-x. View

5.
Banerjee R, Johnson J . A new clone sweeps clean: the enigmatic emergence of Escherichia coli sequence type 131. Antimicrob Agents Chemother. 2014; 58(9):4997-5004. PMC: 4135879. DOI: 10.1128/AAC.02824-14. View